Emerging data suggests that Cilgavimab, formerly known as COV2-2130, demonstrates significant potential as a therapeutic agent against COVID-19. This immunoglobulin exhibits a unique mechanism of operation , in particular binding to the viral ACE2 receptor binding domain with remarkable strength . Preliminary trials show a strong power to block vir